PortalPublikationenPosttraumatic stress disorder symptomatology in the course o...

Posttraumatic stress disorder symptomatology in the course of allogeneic HSCT: a prospective study

Standard

Posttraumatic stress disorder symptomatology in the course of allogeneic HSCT: a prospective study. / Esser, Peter; Kuba, Katharina; Scherwath, Angela; Schirmer, Lena; Schulz-Kindermann, Frank; Dinkel, Andreas; Balck, Friedrich; Koch, Uwe; Kröger, Nicolaus; Götze, Heide; Mehnert, Anja.

in: J CANCER SURVIV, Jahrgang 11, Nr. 2, 04.2017, S. 203-210.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Esser, P, Kuba, K, Scherwath, A, Schirmer, L, Schulz-Kindermann, F, Dinkel, A, Balck, F, Koch, U, Kröger, N, Götze, H & Mehnert, A 2017, 'Posttraumatic stress disorder symptomatology in the course of allogeneic HSCT: a prospective study', J CANCER SURVIV, Jg. 11, Nr. 2, S. 203-210. https://doi.org/10.1007/s11764-016-0579-7

APA

Esser, P., Kuba, K., Scherwath, A., Schirmer, L., Schulz-Kindermann, F., Dinkel, A., Balck, F., Koch, U., Kröger, N., Götze, H., & Mehnert, A. (2017). Posttraumatic stress disorder symptomatology in the course of allogeneic HSCT: a prospective study. J CANCER SURVIV, 11(2), 203-210. https://doi.org/10.1007/s11764-016-0579-7

Vancouver

Esser P, Kuba K, Scherwath A, Schirmer L, Schulz-Kindermann F, Dinkel A et al. Posttraumatic stress disorder symptomatology in the course of allogeneic HSCT: a prospective study. J CANCER SURVIV. 2017 Apr;11(2):203-210. https://doi.org/10.1007/s11764-016-0579-7

Bibtex

@article{7d60c83a8f614b91af92d8c8be95c9a9,
title = "Posttraumatic stress disorder symptomatology in the course of allogeneic HSCT: a prospective study",
abstract = "PURPOSE: Despite the life-threatening character of allogeneic hematopoietic stem cell transplantation (allogeneic HSCT), very few longitudinal research exists on posttraumatic stress disorder (PTSD) symptomatology in this patient group. We investigated prevalence, temporal course and predictors of PTSD symptomatology in this population.METHODS: Patients were assessed before conditioning (T0), 100 days (T1), and 12 months after HSCT (T2). PTSD symptomatology was measured with the PTSD Checklist-Civilian Version. We conducted multilevel modeling and multiple regression analyses.RESULTS: Two hundred thirty-nine patients participated at baseline, 150 at T1, and 102 at T2. Up to 15 % met the criteria for PTSD at least once during the course of assessment. Fifty-two percent showed diagnostic relevant levels of intrusion, 30 % of avoidance, and 33 % of arousal at least once. Apart from arousal, which increased between T0 and T1 (γ = 0.56, p = 0.03), no other severity score significantly differed between time points. Being impaired by pain (γ = 2.89, p < 0.01), pain level (γ = 0.63, p = 0.02), and being female (γ = 3.81, p < 0.01) emerged as significant predictors of PTSD symptomatology when taking into account all time points. Acute plus chronic graft-versus-host-disease and longer hospital stay predicted PTSD symptomatology at T2 (γ = 3.39, p = 0.04; γ = 0.1, p = 0.03).CONCLUSIONS: A considerable number of patients undergoing allogeneic HSCT met the criteria for PTSD. PTSD symptomatology is prominent at all assessment points. Burden of pain, being female, and medical complications are risk factors for elevated levels of PTSD symptomatology.IMPLICATIONS FOR CANCER SURVIVORS: Psychological support should be offered not only after treatment but also in the long-term and even before HSCT. Professionals should be aware of the psychological consequences accompanied by pain and complications.",
keywords = "Journal Article",
author = "Peter Esser and Katharina Kuba and Angela Scherwath and Lena Schirmer and Frank Schulz-Kindermann and Andreas Dinkel and Friedrich Balck and Uwe Koch and Nicolaus Kr{\"o}ger and Heide G{\"o}tze and Anja Mehnert",
year = "2017",
month = apr,
doi = "10.1007/s11764-016-0579-7",
language = "English",
volume = "11",
pages = "203--210",
journal = "J CANCER SURVIV",
issn = "1932-2259",
publisher = "Springer New York",
number = "2",

}

RIS

TY - JOUR

T1 - Posttraumatic stress disorder symptomatology in the course of allogeneic HSCT: a prospective study

AU - Esser, Peter

AU - Kuba, Katharina

AU - Scherwath, Angela

AU - Schirmer, Lena

AU - Schulz-Kindermann, Frank

AU - Dinkel, Andreas

AU - Balck, Friedrich

AU - Koch, Uwe

AU - Kröger, Nicolaus

AU - Götze, Heide

AU - Mehnert, Anja

PY - 2017/4

Y1 - 2017/4

N2 - PURPOSE: Despite the life-threatening character of allogeneic hematopoietic stem cell transplantation (allogeneic HSCT), very few longitudinal research exists on posttraumatic stress disorder (PTSD) symptomatology in this patient group. We investigated prevalence, temporal course and predictors of PTSD symptomatology in this population.METHODS: Patients were assessed before conditioning (T0), 100 days (T1), and 12 months after HSCT (T2). PTSD symptomatology was measured with the PTSD Checklist-Civilian Version. We conducted multilevel modeling and multiple regression analyses.RESULTS: Two hundred thirty-nine patients participated at baseline, 150 at T1, and 102 at T2. Up to 15 % met the criteria for PTSD at least once during the course of assessment. Fifty-two percent showed diagnostic relevant levels of intrusion, 30 % of avoidance, and 33 % of arousal at least once. Apart from arousal, which increased between T0 and T1 (γ = 0.56, p = 0.03), no other severity score significantly differed between time points. Being impaired by pain (γ = 2.89, p < 0.01), pain level (γ = 0.63, p = 0.02), and being female (γ = 3.81, p < 0.01) emerged as significant predictors of PTSD symptomatology when taking into account all time points. Acute plus chronic graft-versus-host-disease and longer hospital stay predicted PTSD symptomatology at T2 (γ = 3.39, p = 0.04; γ = 0.1, p = 0.03).CONCLUSIONS: A considerable number of patients undergoing allogeneic HSCT met the criteria for PTSD. PTSD symptomatology is prominent at all assessment points. Burden of pain, being female, and medical complications are risk factors for elevated levels of PTSD symptomatology.IMPLICATIONS FOR CANCER SURVIVORS: Psychological support should be offered not only after treatment but also in the long-term and even before HSCT. Professionals should be aware of the psychological consequences accompanied by pain and complications.

AB - PURPOSE: Despite the life-threatening character of allogeneic hematopoietic stem cell transplantation (allogeneic HSCT), very few longitudinal research exists on posttraumatic stress disorder (PTSD) symptomatology in this patient group. We investigated prevalence, temporal course and predictors of PTSD symptomatology in this population.METHODS: Patients were assessed before conditioning (T0), 100 days (T1), and 12 months after HSCT (T2). PTSD symptomatology was measured with the PTSD Checklist-Civilian Version. We conducted multilevel modeling and multiple regression analyses.RESULTS: Two hundred thirty-nine patients participated at baseline, 150 at T1, and 102 at T2. Up to 15 % met the criteria for PTSD at least once during the course of assessment. Fifty-two percent showed diagnostic relevant levels of intrusion, 30 % of avoidance, and 33 % of arousal at least once. Apart from arousal, which increased between T0 and T1 (γ = 0.56, p = 0.03), no other severity score significantly differed between time points. Being impaired by pain (γ = 2.89, p < 0.01), pain level (γ = 0.63, p = 0.02), and being female (γ = 3.81, p < 0.01) emerged as significant predictors of PTSD symptomatology when taking into account all time points. Acute plus chronic graft-versus-host-disease and longer hospital stay predicted PTSD symptomatology at T2 (γ = 3.39, p = 0.04; γ = 0.1, p = 0.03).CONCLUSIONS: A considerable number of patients undergoing allogeneic HSCT met the criteria for PTSD. PTSD symptomatology is prominent at all assessment points. Burden of pain, being female, and medical complications are risk factors for elevated levels of PTSD symptomatology.IMPLICATIONS FOR CANCER SURVIVORS: Psychological support should be offered not only after treatment but also in the long-term and even before HSCT. Professionals should be aware of the psychological consequences accompanied by pain and complications.

KW - Journal Article

U2 - 10.1007/s11764-016-0579-7

DO - 10.1007/s11764-016-0579-7

M3 - SCORING: Journal article

C2 - 27796710

VL - 11

SP - 203

EP - 210

JO - J CANCER SURVIV

JF - J CANCER SURVIV

SN - 1932-2259

IS - 2

ER -